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ABSTRACT
In linear regressionmodels, covariate-adjusted analysis is not expected to change the estimates of the treat-
ment effect in the clinical trials with randomized treatment assignment but rather to increase the precision
of the estimates. However, the covariate-adjusted treatment effect estimates are generally not equivalent
to the unadjusted estimates in logistic regression analysis for binary clinical trial data. In this article, we
report the results of a simulation study conducted to quantify the magnitude of difference between the
estimands underlying the two estimators in logistic regression. The simulation results demonstrated that
both unadjusted and adjusted analyses preserved Type I error at the nominal level. The covariate-adjusted
analysis produced unbiased, larger treatment effect estimates, larger standard error, and increased power
comparedwith the unadjusted analysis when the sample sizewas large. The unadjusted analysis resulted in
biased estimates of treatment effect. Analysis results for five phase 3 diabetes trials of the same compound
were consistent with the simulation findings. Therefore, covariate-adjusted analysis is recommended for
evaluating binary outcomes in clinical data.
1. Introduction
Binary outcomes are commonly assessed in clinical trials to
compare treatment groups. For example, in neuroscience tri-
als, a binary outcome of whether a 50% or greater decrease in
scores on the Young Mania Rating Scale from baseline to any
evaluation during the treatment (Yong et al. 1978; Lipkovich,
Duan, and Ahmed 2005) is often evaluated. In diabetes trials, a
clinically meaningful outcome is whether glycated hemoglobin
(HbA1c) reaches the target of <7.0 (ADA 2013; Jiang et al.
2015a, 2015b); another important safety outcome is whether the
patient experiences hypoglycemia (low blood glucose) during
the study (Holman et al. 2007). In oncology trials, medically rel-
evant beneficial changes are often associated with experiencing
a 30% or greater decline in tumor size (Eisenhauer et al. 2009).
Common estimates of treatment effect include the risk differ-
ence (RD), relative risk (RR), and odds ratio (OR) in the anal-
ysis of binary data. Generalized linear models (GLM) with an
identity or log link function are often used for estimation of
RD or RR, respectively. However, these two methods may result
in estimated probabilities outside of [0, 1] interval, and the log
binomial model (for RR) often experiences convergence issues
(Blizzard and Hosmer 2006; Deddens and Peterson 2008). As a
result, logistic regression using GLM with a logit link for esti-
mation of OR remains more popular for analysis of binary data
in clinical trials (Agresti and Hartzel 2000).
In clinical trials, treatment effect can be estimated either
as a covariate-adjusted effect or as an unadjusted effect. When
modeling the relationship between the outcome and treatment
variable using a nonlinear link, the estimands underlying the
CONTACT Honghua Jiang jianghh@lilly.com Lilly Research Labs, Eli Lilly and Co., Indianapolis, IN .
two estimators are different despite the fact that treatment
is assigned independently of covariates. The unadjusted esti-
mate is marginal or population-averaged, whereas the adjusted
estimate is conditional on subject-specific characteristics
included in the model. It is of interest to quantify the magnitude
of the difference between the two estimands for binary data
analysis with logistic regression.
In randomized clinical trials, baseline covariates are not
expected to be correlated with treatment assignment. There-
fore, in linear regression models covariate adjustment is not
expected to change estimates of the treatment effect, but rather
to increase the precision of the estimate. However, this is not
the case for nonlinear regression models (Gail, Wieand, and
Piantadosi 1984; Hauck et al. 1991; Canner 1991; Robinson
and Jewell 1991; Hauck, Anderson, and Marcus 1998; Kernan
et al. 1999; Steyerberg, Bossuyt, and Lee 2000; Raab, Day, and
Sales 2000; Pocock et al. 2002; Ford and Norrie 2002; Her-
nandez, Steyerberg, andHabbema 2004) The covariate-adjusted
treatment effect estimates are generally not equivalent to the
unadjusted treatment effect estimates in logistic regressionmod-
els (Gail, Wieand, and Piantadosi 1984). Robinson and Jewell
(1991) and Begg and Lagakos (1993) showed that adjustment for
prognostic covariates always results in an increase in the stan-
dard error as well as the treatment effect estimate compared to
the unadjusted analysis.However, the efficiencywith adjustment
for covariates is at least as high as without adjustment.
Hernandez, Steyerberg, and Habbema (2004) and Nicholas
et al. (2015) conducted simulation studies to compare logis-
tic regression analyses with or without adjustment for one
©  American Statistical Association
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dichotomous covariate. Hernadez et al. (2004) showed that
covariate-adjusted analysis increased power to detect the treat-
ment effect without inflation of Type I error. Nicholas et al.
(2015) showed that in both superiority and noninferiority set-
tings, unadjusted analysis resulted in biased treatment effect
estimates and deflated standard errors, and decreased power and
nominal or conservative Type I error in the context of superior-
ity. They did not study the effect of covariate adjustment with
continuous covariates.
Jiang et al. (2015a, 2015b) conducted simulation studies to
compare different methods for analysis of repeated binary data
with or without adjustment for one continuous covariate. They
showed that adjusted analyses were associated with larger esti-
mates of treatment effect, larger standard errors, and increased
power without inflation of the Type I error. However, they
did not evaluate the bias due to the nature of data generation.
Ciolino et al (2013) evaluated the effect of adjusting one continu-
ous covariate in the analysis of binary outcome. But they focused
on the estimates of relative risk, not odds ratio.
To fix ideas, consider a simple adjusted model where the
binary clinical outcome depends on treatment (T) and a single
covariate (X) through the inverse logit link:
P (Y = 1|X,T ) = 1/ [1 + exp (−β0 − β1T − β2X )] . (1)
Then, our covariate-adjusted treatment effect (estimand) is
simply defined by themodel parameter β1. This is because β1 =
log ( P(Y=1|X,T=1)1−P(Y=1|X,T=1)
1−P(Y=1|X,T=0)
P(Y=1|X,T=0) ), regardless of the marginal
distribution of covariate X, assuming that model (1) is correctly
specified.
Now we define an unadjusted estimate as β˜1 =
log ( P(Y=1|T=1)1−P(Y=1|T=1)
1−P(Y=1|T=0)
P(Y=1|T=0) ), where the probabilities have
to be computed under model (1). Therefore the marginal
probability of response can be obtained by integration:
P (Y = 1|T = 1) =
∫
P (Y = 1|X = x,T = 1) f (x) dx.
As a result, the unadjusted treatment effect β˜1 expected in a
given population of patients will depend on the distribution of
covariate X in that population.
Our algebra shows the relationship between the model for-
mulation conditional on X on the one hand and marginal
over X on the other (see the appendix), for a number of
scenarios. First, when a probit rather than a logit link is
assumed and X is assumed standard normally distributed,
then the model marginal over X is of a probit nature as well,
but with attenuation of the other two regression coefficients,
by the amount
√
β2
2 + 1. Second, a similar result is found
for a logit link and X following the bridge distribution pro-
posed by Wang and Louis (2003, 2004). The attenuation fac-
tor then is
√
1 + 3
π2
β2
2. It is important to see that, in both
cases, there is no shift, merely attenuation. Also, the attenua-
tion effect depends solely on the β22, and hence is indepen-
dent of its sign. Calculations were done with the bridge rather
than the normal distribution, because a logit link and a nor-
mally distributed X does not allow for a closed-form solution.
Third, when X is uniform over an interval [−k/2, k/2], then
the marginalized model allows for a closed form, but is no
longer of a logistic type. Also here, though, dependence is on
| β2| only, not on its sign.
Fourth, when X follows a uniform on the unit interval, then
the sign of β2 does have an impact, a result of asymmetry
around zero.
The above considerations are useful as well to get some intu-
ition as to what an unmeasured or unknown confounder X
brings to the model. In such a case, one would be fitting the
marginal model, even though ideally the model including X
should be fitted, but unfortunately that is impossible. The gen-
eral finding is that the treatment effect will be attenuated for
symmetric unmeasured X’s, with additional implications in the
asymmetric case. The algebra shows that the precise nature of
the impact depends on the distribution of X. For a general treat-
ment of unmeasured confounding, see Vander Weele and Arah
(2011).
The above discussion provides us with the rationale for pre-
ferring the covariate-adjusted estimandover the unadjusted one:
the former provides an assessment of treatment effect that does
not depend on the distribution of the covariate in a particular
population (as long as the logistic model is correctly specified),
whereas the latter will need to be recomputed each time a popu-
lation with somewhat different covariate distribution is consid-
ered. However under some circumstances, an unadjusted anal-
ysis can be preferred by the study team. What we emphasize,
however, is that choosing an estimand always needs to be well-
motivated.
In this article, we will examine the impact of adjusting for
a continuous covariate in the analysis of the binary outcomes
with logistic regression model for the estimation of odds ratio,
focusing on evaluation of bias, power, and Type I error through
simulations. When evaluating bias we assume that the estimand
of interest is the covariate-adjusted treatment effect and we
expect to see some “bias” under unadjusted analyses. Therefore,
we conducted extensive simulations to quantify the difference
between the two estimators under various conditions. Simula-
tion settings are described in Section 2, and simulation results
are presented in Section 3. In Section 4, application to clinical
trial data is illustrated. Section 5 concludes with a discussion.
2. Simulation Settings
Simulation studies were conducted using SAS® statistical soft-
ware (SAS 2008) for a clinical trial with two treatment groups
and equal allocation, one baseline continuous covariate, and a
binary outcome. In the simulated trial, we assumed either (a) no
treatment effect on outcome to evaluate the Type I error, or (b)
a certain level of treatment effect to evaluate power. We focused
on the sample sizes of 50 and 300 per treatment group to mimic
phase 2 and phase 3 trial settings, respectively. For each simu-
lation setting, 10,000 datasets were generated. The simulation
involved the following steps:
1. Simulate a continuous covariate, X, from a normal dis-
tribution, X ∼ N (30, 152).
2. Assign X value to one of the two treatment groups and
ensure an equal sample size across treatment groups
(N).
3. Simulate a response, Y (0, 1), based on the probability
P with the following underlying assumed relationship
128 H. JIANG ET AL.
Table . Summary of analysis results from , simulations with β = −, β = , and with/without a covariate eﬀect (Type I error rate comparison) with incidence rate
of %/% for each arm.
Unadjusted logistic Adjusted logistic
N β β̂1 Bias SE MSE Cov (%) Rej. rate (%) β̂1 Bias SE MSE Cov (%) Rej. rate (%)
  . . . .  . . . . .  .
  . . . .  . . . . .  .
  . . . .  . . . . .  .
  . . . .  . . . . .  .
  . . . .  . . . . .  .
  . . . .  . . . . .  .
 . − . − . . .  . − . − . . .  .
 . . . . .  . . . . .  .
 . . . . .  . . . . .  .
 . . . . .  . . . . .  .
 . . . . .  . − . − . . .  .
 . . . . .  . . . . .  .
NOTE: Cov: coverage of % CI; Rej. rate: rejection rate; β: intercept; β: treatment eﬀect; β: covariate eﬀect.
between P, X, and treatment assignment, T:
P (Y = 1|X,T ) = 1/ [1 + exp (−β0 − β1T − β2X )] ,
where β1 is the treatment effect, β2 is the covariate
effect, T = 0 for assignment to comparator, and T = 1
for assignment to active treatment.
4. Repeat Steps 1–3 2N times to simulate a trial with a sam-
ple size of N per treatment group.
5. Fit a logistic regression model to the simulated data with
or without adjusting for the continuous covariate, cap-
turing the treatment effect estimates, standard errors,
and p values associated with treatment effect.
6. Repeat Steps 1–5 10,000 times.
The performance of the covariate-adjusted and unadjusted
analyses was evaluated based on bias ( βˆ1− β1) in scenarios
when there was no difference between treatments, and bias and
relative bias ( βˆ1 −β1
β1
×100) in scenarios where treatments dif-
fered. Analyses were also compared based on 95% confidence
interval (CI) coverage (using normal theory approximation),
standard errors (SE) (average of SEs from the 10,000 simula-
tions),mean squared error (MSE), Type I error rate for scenarios
with no difference between treatments, and power for scenarios
where treatments differed. βˆ1 is the estimate of log odds ratio
for unadjusted or adjusted analysis. β1 is the true log odds ratio.
3. Simulation Results
Table 1 presents simulation results from 10,000 datasets with no
treatment effect (i.e., β1= 0), with or without a covariate effect
( β2) for different sample sizes. In all cases except when N = 50
for each treatment group, both the covariate-adjusted and unad-
justed analyses provided essentially unbiased treatment effect
estimates and preserved the Type I error close to the nominal
level. Both the adjusted and unadjusted analyses were associated
with moderate bias when N = 50. When there was no covari-
ate effect, both the adjusted and unadjusted analyses produced
almost identical treatment effect estimate, SE,MSE, 95%CI cov-
erage, and Type I error rate. When there was a covariate effect,
the adjusted analysis was associated with greater SE and MSE.
However, other parameters were similar to those of the unad-
justed analysis.
Table 2 shows simulation results from 10,000 datasets with
a certain level of treatment effect (β1 = 0.7), with or without
a covariate effect for different sample sizes. When there was
no covariate effect, both the adjusted and unadjusted analyses
produced almost identical treatment effect estimates, SE, MSE,
95%CI coverage, and power, with essentially unbiased estimates
(except for when N = 50 both analyses were associated with
moderate relative bias around 8%). When there was a covari-
ate effect, adjusted analysis still produced essentially unbiased
estimates (except for when N = 50 with moderate relative bias
Table . Summary of analysis results from , simulations with β = −, β = ., and with/without a covariate eﬀect with incidence rate of %/% for one arm, and
%/% for the other arm.
Unadjusted logistic Adjusted logistic
N β β̂1 Bias Rel. Bias (%) SE MSE Cov (%) Power (%) β̂1 Bias Rel. Bias (%) SE MSE Cov (%) Power (%)
  . . . . .  . . . . . .  .
  . . . . .  . . . . . .  .
  . . . . .  . . . . . .  .
  . . . . .  . . . . . .  .
  . . . . .  . . . . . .  .
  . . . . .  . . . . . .  .
 . . − . − . . .  . . . . . .  .
 . . − . − . . .  . . . . . .  .
 . . − . − . . .  . . . . . .  .
 . . − . − . . .  . . . . . .  .
 . . − . − . . .  . . . . . .  .
 . . − . − . . .  . . . . . .  .
NOTE: Rel Bias: relative Bias; Cov: coverage of % CI; β: intercept; β: treatment eﬀect; β: covariate eﬀect.
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Table . Summary of analysis results from , simulations with β = −, β = . (a positive covariate eﬀect) and diﬀerent levels of treatment eﬀect with incidence
rate of % for one arm, and % to % for the other arm.
Unadjusted logistic Adjusted logistic
N β β̂1 Bias Rel. Bias (%) SE MSE Cov (%) Power (%) β̂1 Bias Rel. Bias (%) SE MSE Cov (%) Power (%)
 . . − . − . .  . . .  . .  .
. . − . − . .  . . .  . .  .
. . − . − . .  . . .  . .  .
. . − . − . .  . . .  . .  .
. . − . − . .  . . .  . .  .
. . − . − . .  . . .  . .  .
. . − . − . .  . . .  . .  .
. . − . − . .  . . .  . .  .
 . . − . − . .  . . .  . .  .
. . − . − . .  . . .  . .  .
. . − . − . .  . . .  . .  .
. . − . − . .  . . .  . .  .
. . − . − . .  . . .  . .  .
. . − . − . .  . . .  . .  .
. . − . − . .  . . .  . .  .
. . − . − . .  . . .  . .  .
NOTE: Rel Bias: relative Bias; Cov: coverage of % CI; β: intercept; β: treatment eﬀect; β: covariate eﬀect.
around 9%), and close to nominal CI coverage. However, the
unadjusted analysis was associated with biased treatment effect
estimates (relative bias ranging from 20% to 24%), which were
smaller than the true value, and resulted in smaller than nomi-
nal CI coverage. SEs from the unadjusted analysis were smaller
than those from adjusted analysis. Despite smaller standard
errors, unadjusted analyses resulted in reduced power (by up to
12% compared to covariate-adjusted) due to negatively biased
estimates of treatment effect. MSEs were similar from both
analyses.
Simulation results for scenarios with different levels of treat-
ment effect (β1 assuming values from 0.3 to 1.0) are presented
in Tables 3 and 4. Table 3 shows results for positive covari-
ate effect (i.e., with the same sign as treatment effect), whereas
Table 4—for scenarios with negative covariate effect. In the pres-
ence of a covariate effect (regardless of the sign), an unadjusted
analysis was associated with biased estimates and poor 95% CI
coverage: the larger the treatment effect, the greater the bias
and smaller than nominal coverage level. However, the rela-
tive biases were relatively stable with the same covariate effect
regardless of the level of the treatment effect and sample size.
The SEs were consistently smaller with the unadjusted anal-
ysis compared to the adjusted analysis. The adjusted analysis
produced unbiased estimates when the sample size was large
(N = 300), and moderately biased estimates when the sam-
ple size was small (relative bias about 10%, N = 50). The 95%
CI coverage was at nominal level with the adjusted analysis
regardless of the sample size and treatment effect. The adjusted
analysis was associated with significantly increased power com-
pared to the unadjusted analysis (up to 29% absolute difference).
MSEs were larger with the adjusted analysis when the sample
size was small (N = 50 per arm) and smaller when the sample
size was large (N = 300 per arm) compared to the unadjusted
analysis.
Simulation results summarizing the performance of unad-
justed versus adjusted analyses for scenarios with different lev-
els of covariate effect are displayed in Table 5. The unadjusted
analysis was associated with biased estimates and poor 95% CI
coverage: the larger the covariate effect, the greater the bias, rela-
tive bias, and smaller than nominal level of the CI coverage. The
Table . Summary of analysis results from , simulations with β = , β = −. (a negative covariate eﬀect) and diﬀerent levels of treatment eﬀect with incidence
rate of % for one arm and % to % for the other arm.
Unadjusted logistic Adjusted logistic
N β β̂1 Bias Rel. Bias (%) SE MSE Cov (%) Power (%) β̂1 Bias Rel. Bias (%) SE MSE Cov (%) Power (%)
 . . − . − . .  . . .  . .  .
. . − . − . .  . . .  . .  .
. . − . − . .  . . .  . .  .
. . − . − . .  . . .  . .  .
. . − . − . .  . . .  . .  .
. . − . − . .  . . .  . .  .
. . − . − . .  . . .  . .  .
. . − . − . .  . . .  . .  .
 . . − . − . .  . . .  . .  .
. . − . − . .  . . .  . .  .
. . − . − . .  . . .  . .  .
. . − . − . .  . . .  . .  .
. . − . − . .  . . .  . .  .
. . − . − . .  . . .  . .  .
. . − . − . .  . . .  . .  .
. . − . − . .  . . .  . .  .
NOTE: Rel Bias: relative Bias; Cov: coverage of % CI; β: intercept; β: treatment eﬀect; β: covariate eﬀect.
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Table . Summary of analysis results from , simulations with β = −, β = ., and diﬀerent levels of a covariate eﬀect with incidence rate from % to % for one
arm and % to % for the other arm.
Unadjusted logistic Adjusted logistic
N β β̂1 Bias Rel. Bias (%) SE MSE Cov (%) Power (%) β̂1 Bias Rel. Bias (%) SE MSE Cov (%) Power (%)
 . . − . −  . .  . . .  . .  .
. . − . −  . .  . . .  . .  .
. . − . −  . .  . . .  . .  .
. . − . −  . .  . . .  . .  .
. . − . −  . .  . . .  . .  .
 . . − . −  . .  . . .  . .  .
. . − . −  . .  . . .  . .  .
. . − . −  . .  . . .  . .  .
. . − . −  . .  . . .  . .  .
. . − . −  . .  . . .  . .  .
NOTE: Rel Bias: relative Bias; Cov: coverage of % CI; β: intercept; β: treatment eﬀect; β: covariate eﬀect.
adjusted analysis produced unbiased estimates when the sample
size was large, andmoderately biased estimates when the sample
sizewas small, greater power, but larger SE comparedwith unad-
justed analysis. In general, the adjusted analysis was associated
with larger MSEs when the sample size was small and smaller
MSEs when the sample size was large.
Power comparisons for scenarios with a certain (positive)
level of covariate effect and different levels of treatment effect
and sample size are shown in Figure 1. Significantly increased
power was associated with the adjusted analysis compared to the
unadjusted analysis.
We also conducted additional simulations generating data
with two covariates: one that is prognostic and one that is not
using the following formula:
P (Y = 1|X,T,Z) = 1/[1 + exp (−β0 − β1T − β2X − β3Z)],
where X, Y, T, and P were the same as described before,
Z was a nonprognostic covariate with a normal distribution,
Figure . Power comparison from , simulations with (a) β = −, β = ., N =  per arm, and diﬀerent levels of treatment eﬀect with incidence rate of % for
one arm, and % to % for the other arm; (b) β = −, β = ., β = ., and diﬀerent sample sizes with incidence rate of % for one arm and % for the other arm.
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Table . Summary of analysis results from , simulations with β = −, β = ., β =  and diﬀerent levels of treatment eﬀect with incidence rate of % for one
arm, and % to % for the other arm.
Unadjusted logistic Adjusted logistic (nonprognostic covariate) Adjusted logistic (prognostic covariate)
Rel. Bias Cov Power Rel. Bias Cov Power Rel. Bias Cov Power
N β̂1 β̂1 Bias (%) SE MSE (%) (%) β̂1 Bias (%) SE MSE (%) (%) β̂1 Bias (%) SE MSE (%) (%)
 . . − . − . .  . . − . − . .  . . .  . .  .
. . − . − . .  . . − . − . .  . . .  . .  .
. . − . − . .  . . − . − . .  . . .  . .  .
. . − . − . .  . . − . − . .  . . .  . .  .
. . − . − . .  . . − . − . .  . . .  . .  .
. . − . − . .  . . − . − . .  . . .  . .  .
. . − . − . .  . . − . − . .  . . .  . .  .
. . − . − . .  . . − . − . .  . . .  . .  .
 . . − . − . .  . . − . − . .  . . .  . .  .
. . − . − . .  . . − . − . .  . . .  . .  .
. . − . − . .  . . − . − . .  . . .  . .  .
. . − . − . .  . . − . − . .  . . .  . .  .
. . − . − . .  . . − . − . .  . . .  . .  .
. . − . − . .  . . − . − . .  . . .  . .  .
. . − . − . .  . . − . − . .  . . .  . .  .
. . − . − . .  . . − . − . .  . . .  . .  .
NOTE: Rel Bias: relative Bias; Cov: coverage of % CI; β: intercept; β: treatment eﬀect; β: prognostic covariate eﬀect; β: nonprognostic covariate eﬀect.
Z∼N (20,102). Then, we compared amodel that adjusts for only
the prognostic covariate with a model that adjusts for only the
nonprognostic covariate (Table 6). The difference between the
analysis of adjusting for the prognostic covariate and the unad-
justed analysis was consistent with previous results. Adjusting
for the nonprognostic covariate yielded almost identical results
as the unadjusted analysis.
4. Clinical Trial Examples
Covariate-adjusted and unadjusted analyses were applied to
data from five diabetes clinical trials in which an experimental
drug (treatment) was compared with different active controls
over 52 weeks. The analyses were focused on percentage of
patients whose 52 week endpoint HbA1c was less than 7.0%.
Data from all those who withdrew were removed from the
analysis. Results of treatment comparisons for different analyses
are presented in Table 7 and Figure 2. Covariate-adjusted anal-
ysis produced larger treatment effects compared to unadjusted
analysis with larger standard errors and smaller p-values in
all studies except for study 4, where adjusted and unadjusted
analyses produced comparable treatment effects and standard
errors. The reason for that is that the treatment group had
slightly lower baseline HbA1c values (compared to the control
group) in study 4 and slightly higher values in all other studies.
The differences (treatment − comparator) in baseline HbA1c
were 0.03%, 0.09%, 0.05%, −0.05%, 0.12% for study 1 to 5,
respectively.
5. Discussion
The simulation results demonstrated that, when the sample
size was large and regardless of positive or negative covariate
effect, the covariate-adjusted analysis produced unbiased, larger
treatment effect estimates, larger standard error, and increased
power compared with the unadjusted analysis without infla-
tion of Type I error in the analysis of binary data. The unad-
justed analysis was associated with biased estimates: the larger
the treatment effect, the larger the bias; the larger the covari-
ate effect, the larger the bias. When there was no covariate
effect, the adjusted analysis produced almost identical estimates
of treatment effect, standard errors, mean squared error, and
power as the unadjusted analysis. Therefore, according to Inter-
nationalConference onHarmonization guidelines (Lewis 1999),
the covariate adjustment analysis can be prespecified in the sta-
tistical analysis plan, though we may not be quite sure about the
level of the covariate effect on the outcome at the design stage.
Even if there is no covariate effect, adjusting for the covariate will
not havemuch detrimental effect on estimating treatment effect.
However, if there is a covariate effect (regardless of whether it
is positive or negative), the benefit of adjusting the covariate is
obvious.
Analysis results for binary data with a small sample size
should be interpreted with caution. The simulation results
demonstrated that even the covariate-adjusted analysis could be
associated with moderately biased estimates.
The unadjusted analysis is a marginal or population aver-
aged analysis without consideration of heterogeneity among
Table . Analysis results from ﬁve diabetes clinical studies.
Unadjusted logistic Adjusted logistic
Study Coef SE LL UL p Value Coef SE LL UL p Value
 . . . . <. . . . . <.
 . . . . <. . . . . <.
 . . . . . . . . . .
 . . . . . . . . . .
 . . . . <. . . . . <.
NOTE: Coef: log odds ratio; LL: lower limit of % conﬁdence interval; UL: upper limit of % conﬁdence interval.
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Figure . Log odds ratio and % CI by study.
patients, whereas the adjusted analysis is a population-averaged
analysis that is conditional on specific subject characteristics
(and in this sense is a step toward subject-specific analysis). The
adjusted analysis is recommended due to the more individual-
ized, unbiased treatment effect estimates corrected for covariate
imbalance, resulting in gain in power, and reduction in effective
sample size (Pocock 2002).
Simulations are always limited to the cases considered in the
study. We only considered the case of adjusting for one contin-
uous, normally distributed variable. When adjusting for more
than one covariate, the same conclusion for treatment estimates,
SE, and power would be expected. A loss of efficiencymay occur
if adjustment is made for a large number of uncorrelated covari-
ates. To determine howmany of such unnecessary covariates can
be included in a logistic regression model before performance
begins to suffer could be a future research topic.
Appendix: TheMarginal Probability of Response for
the Unadjusted Analysis
1. Using probit link andXwith standard normal distribution:
∫
φ(β0 + β1T + β2x) 1√
2π
exp
(
−x
2
2
)
dx
= 1
2π
∫ +∞
x=−∞
dx
∫ t=η+β2x
t=−∞
exp
(
− t
2 + x2
2
)
dt,
where η = β0 + β1T
= 1
2π
∫ 0
s=−∞
ds
∫ +∞
x=−∞
exp
(
− (s + η + β2x)
2 + x2
2
)
dx,
where t − η − β2x = s
= 1
2π
∫ 0
s=−∞
ds
∫ +∞
x=−∞
exp
[
− (s + η)
2
2
(
β2
2 + 1)
]
× exp
{
−1
2
[
x
√
β2
2 + 1 + (s + η) β2√
β2
2 + 1
]2}
dx,
= 1√
2π
∫ 0
s=−∞
exp
[
− (s + η)
2
2
(
β2
2 + 1)
]
ds
1√
2π
×
∫ +∞
x=−∞
exp
{
−1
2
[
x
√
β2
2 + 1 + (s + η) β2√
β2
2 + 1
]2}
dx
while,
(s + η)2 + 2 (s + η) β2x +
(
β2
2 + 1) x2
=
[
x
√
β2
2 + 1 + (s + η) β2√
β2
2 + 1
]2
+ (s + η)
2
β2
2 + 1
Then
1√
2π
∫ +∞
x=−∞
exp
⎧⎨⎩−12
[
x
√
β2
2 + 1 + (s + η) β2√
β2
2 + 1
]2⎫⎬⎭ dx
= 1√
β2
2 + 1
And
1√
2π
∫ 0
s=−∞
exp
[
− (s + η)
2
2
(
β2
2 + 1)
]
ds
=
√
β2
2 + 1 1√
2π
∫ v= η√
β22+1
v=−∞
exp
(
−v
2
2
)
dv
=
√
β2
2 + 1 φ
(
η√
β2
2 + 1
)
Where,
v = s + η√
β2
2 + 1
, ds =
√
β2
2 + 1 dv
Hence, ∫
φ(β0 + β1T + β2x) 1√
2π
exp
(
−x
2
2
)
dx
= φ
(
β0 + β1T√
β2
2 + 1
)
(known results)
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2. Using logit link and X with bridge distribution (Wang and
Louis 2003, 2004)∫
exp (β0 + β1T + β2x)
1 + exp (β0 + β1T + β2x) f (β2x) d (β2x)
= expφ (β0 + β1T )
1 + expφ (β0 + β1T )
Where,
f (β2x) = 12π .
1
2π cosh (φβ2x) + cos (φπ )
φ = 1√
1 + 3
π2
β2
2
Again the sign of β2 is not important.
3. Using logit link and X with uniform [ −k2 ,
k
2 ]:∫
exp (β0 + β1T + β2x)
1 + exp (β0 + β1T + β2x) f (x) dx
= 1
k
∫ k/2
−k/2
exp (β0 + β1T + β2x)
1 + exp (β0 + β1T + β2x)dx
= 1
k
.
1
β2
ln
[
1 + exp (β0 + β1T + β2 k2 )
1 + exp (β0 + β1T − β2 k2 )
]
This one is also symmetric in β2.
Replace β2 by −β2,
1
k
.
1
−β2 ln
[
1 + exp (β0 + β1T − β2 k2 )
1 + exp (β0 + β1T + β2 k2 )
]
= 1
k
.
1
−β2
{
− ln
[
1 + exp (β0 + β1T + β2 k2 )
1 + exp (β0 + β1T − β2 k2 )
]}
= original expression
4. Using logit link and X with uniform [0, 1]:
∫
exp (β0 + β1T + β2x)
1 + exp (β0 + β1T + β2x) f (x) dx
=
∫ 1
0
exp (β0 + β1T + β2x)
1 + exp (β0 + β1T + β2x)dx
= 1
β2
ln
[
1 + exp (β0 + β1T + β2x)
] ∣∣∣∣10
= 1
β2
ln
[
1 + exp (β0 + β1T + β2)
1 + exp (β0 + β1T )
]
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